Duragesic Patch
Duragesic patches have been subject to a recall due to the medication leaking from the patch as a result of improper sealing of their edges.
Approved by the U.S. Food and Drug Administration (FDA) in 1990, the Duragesic patch releases fentanyl, a strong opioid, through the skin at a fixed rate for 72 hours. The patch is recommended for patients who are already on and tolerant to opioid therapy, and require continuous opioid administration.
Duragesic patches have been subject to a recall due to the medication leaking from the patch as a result of improper sealing of their edges. If the medication leaks out of the patch, exposure to the medication can result in inadvertent ingestion or increased transdermal absorption of the active opiate component fentanyl, leading to potentially life-threatening complications. In addition, leakage of the medication could lead to inadequate dosing, resulting in treatment failure and/or opiate withdrawal.
Janssen Pharmaceuticals, the manufacturer of the Duragesic patch notified healthcare professionals of an expanded recall of the Duragesic 75 mcg/h, in February 2004. On July 15, 2005 the FDA issued a Public Health Advisory concerning the use of Duragesic Patches (Fentanyl transdermal) in response to reports of deaths in patients using the patch.
We are currently evaluating cases involving deaths associated with the use of these patches.
Contact an Alabama personal injury lawyer at Taylor Martino Zarzaur for a free initial consultation to review your case.
Taylor Martino Zarzaur serves clients along the entire Gulf Coast, including Mobile, Pensacola, Montgomery, Orange Beach, Gulf Shores and Baldwin County, Alabama, Mississippi and Florida.
